-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $148

Benzinga·12/17/2025 20:10:42
Listen to the news
Canaccord Genuity analyst William Plovanic maintains TransMedics Group (NASDAQ:TMDX) with a Buy and raises the price target from $147 to $148.